Researchers are increasingly focused on retatrutide, a innovative treatment from Eli Lilly, as a possible breakthrough in body reduction . Unlike many previous approaches, retatrutide is a double -action receptor targeting both GLP-1 and GIP, chemicals that influence appetite and blood glucose co